Research collaborations

PartneringWe have a successful record of research collaborations, in areas such as oncology, with partners including Novartis (now advanced into Phase II clinical studies), Servier, Genentech, GSK, Lundbeck, Asahi Kasei Pharma and Taisho. Vernalis’ structure and fragment-based drug discovery expertise is available to support a variety of target-specific collaborations.

We continue to seek further research collaborations. Contact us to discuss our particular research expertise, with a view to possible joint research projects.
Contact us >

See our current research collaborations

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch